Business, cardiology

Biosense Webster and Medtronic collaborate to advance cardiac arrhythmia care

10 May 2007

Diamond Bar, Calif. & Minneapolis, USA. Biosense Webster, Inc. and Medtronic, Inc. (NYSE:MDT), have announced plans to collaborate on a clinical trial, educational initiatives and a product development program, to advance the care of patients with cardiac arrhythmias.

Under the terms of the agreement, the two companies plan to collaborate in three key areas of interest: a clinical trial, a technology development initiative and educational programs. The companies intend to design the clinical trial to create a new care pathway for identifying candidates most likely to have a successful ablation treatment outcome and increase the acceptance of ablation therapy.

The initiative was announced at Heart Rhythm 2007, the US Heart Rhythm Society’s 28th Annual Scientific Sessions, taking place in Denver May 9-12.

“This new strategic alliance will leverage the unique resources and technologies of the two companies together, and will benefit the millions of patients who suffer from cardiac arrhythmias around the world,” said Roy Tanaka, President, Biosense Webster, Inc.

“Medtronic is intently focused on researching and exploring ways to utilize existing or new technologies for electrophysiologists to better identify and treat patients with cardiac arrhythmias,” said Steve Mahle, President of Medtronic’s Cardiac Rhythm Disease Management business. “This collaboration will begin by bringing the unique competencies of imaging and navigation together with diagnostics and monitoring in an effort to improve the electrophysiologist’s capability in identifying and treating patients. We look forward to collaborating with Biosense Webster to deliver exciting results for our customers.”

In addition, the two companies will work together to advance patient care through a joint research and development program. The companies plan to integrate specific technologies to provide novel, new solutions for the treatment of complex cardiac arrhythmias.

Lifetime education of physicians is a hallmark of both Biosense Webster and Medtronic. Through this relationship, the companies will collaborate to combine resources to extend existing educational opportunities as well as create new instructional programs for electrophysiologists and allied health professionals who work in the arrhythmias field.

“With Biosense Webster, we can continue our commitment to education of physicians at all stages of their career,” said Mahle. “The field of electrophysiology is always changing and advancing and it is vital that physicians and other health care professionals who work in this field are up-to-date on the latest technologies designed to help patients.”

To top

To top